Clinical trial
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or…
NCT00346216 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00346216 |
|---|---|
| Title | Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen |
| Official title | A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen |
| Acronym | PRECISION |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Collaborators | The Cleveland Clinic |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Arthritis, Rheumatoid |
| Intervention type | Drug |
| Interventions | celecoxib, Ibuprofen, Naproxen |
| Enrollment | 24,081 |
| Start date | Oct 4, 2006 |
| Primary completion | Apr 12, 2016 |
| Completion | Apr 12, 2016 |
| First posted | Jun 29, 2006 |
| Last update posted | Mar 3, 2021 |
| Countries | Australia, Brazil, Canada, Colombia, Costa Rica, Hong Kong, Mexico, Panama, Peru, Philippines, Taiwan, Ukraine and 1 more |
At a glance
- 1,000+ Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: